CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $4.57B, above the global median of $1.15B
- PositionOperating margin is 38.4%, higher than 95% of its Biotechnology peers (median -23.8%)
- Interpretations7 currently firing — 7
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.26%
Annual Rate
INR 2.00Paid unknown
Payout Ratio
0.0%Sustainable
Last Ex-Dividend
Jun 25, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
436.45BINR4.57B · vs all stocks (USD)
Trailing P/E
74.64xvs Biotechnology peers
Revenue (TTM)
21.29BINR223.15M · vs all stocks (USD)
Profit Margin
27.79%vs Biotechnology peers
52-Week Change
6.39%vs all stocks
Forward Annual Dividend Yield
0.26%vs all stocks
Market Capitalization
436.45BINR4.57B · vs all stocks (USD)
Enterprise Value
427.61BINR4.48B · vs all stocks (USD)
Trailing P/E
74.64xvs Biotechnology peers
Forward P/E
49.57xvs Biotechnology peers
PEG Ratio
1.43xvs Biotechnology peers
Price to Sales (TTM)
20.50xvs Biotechnology peers
Price to Book (MRQ)
14.35xvs Biotechnology peers
Enterprise to Revenue
20.08xvs Biotechnology peers
Enterprise to EBITDA
50.89xvs Biotechnology peers
Gross Margin
64.73%vs Biotechnology peers
Profit Margin
27.79%vs Biotechnology peers
Operating Margin
38.37%vs Biotechnology peers
Return on Assets (TTM)
14.20%vs Biotechnology peers
Return on Equity (TTM)
21.71%vs Biotechnology peers
Revenue (TTM)
21.29BINR223.15M · vs all stocks (USD)
Revenue per Share (TTM)
37.95INRUpdated Jul 19, 2026Quarterly Revenue Growth
26.00%vs Biotechnology peers
Gross Profit (TTM)
12.75BINR133.62M · vs all stocks (USD)
EBITDA (TTM)
9.85BINR103.18M · vs all stocks (USD)
Net Income (TTM)
5.92BINR62.02M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
129.70%vs Biotechnology peers
Operating Cash Flow (TTM)
8.44BINR88.50M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
5.55BINR58.15M · vs all stocks (USD)
Forward Annual Dividend Rate
2.00INRUpdated Jul 19, 2026Forward Annual Dividend Yield
0.26%vs all stocks
Trailing Annual Dividend Rate
2.00INRUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.26%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
21.24BINRFY2026 · Mar 31, 2026Cost of Goods Sold
8.12BINRFY2026 · Mar 31, 2026Gross Profit
13.12BINRFY2026 · Mar 31, 2026Operating Income
7.05BINR73.91M · vs all stocks (USD)
Pre-tax Income
8.24BINRFY2026 · Mar 31, 2026Income Tax Expense
2.32BINRFY2026 · Mar 31, 2026Net Income
5.92BINRFY2026 · Mar 31, 2026EBIT
8.31BINRFY2026 · Mar 31, 2026EBITDA (Income Statement)
9.80BINRFY2026 · Mar 31, 2026Research & Development
181.54MINRFY2026 · Mar 31, 2026Selling, General & Administrative
188.36MINRFY2026 · Mar 31, 2026Other Operating Expenses
1.57BINRFY2026 · Mar 31, 2026Non-operating Interest Income
792.70MINRFY2026 · Mar 31, 2026Non-operating Interest Expense
65.41MINRFY2026 · Mar 31, 2026Preferred Stock Dividends
0.00INRFY2026 · Mar 31, 2026Operating Cash Flow
9.44BINRFY2026 · Mar 31, 2026Free Cash Flow
7.37BINRFY2026 · Mar 31, 2026Cash & Cash Equivalents (End of Period)
2.75BINRFY2026 · Mar 31, 2026Starting Profit (CF Statement)
8.24BINRFY2026 · Mar 31, 2026Stock-based Compensation
158.59MINRFY2026 · Mar 31, 2026Other Non-cash Items
-723.76MINRFY2026 · Mar 31, 2026Change in Accounts Receivable (CF)
-1.26BINRFY2026 · Mar 31, 2026Change in Other Assets/Liabilities
3.02BINRFY2026 · Mar 31, 2026Capital Expenditures
-2.07BINRFY2026 · Mar 31, 2026Purchase of Investments
-5.78BINRFY2026 · Mar 31, 2026Sale of Investments
87.96MINRFY2026 · Mar 31, 2026Net Investing Cash Flow
-7.77BINRFY2026 · Mar 31, 2026Long-term Debt Payments
-192.94MINRFY2026 · Mar 31, 2026Net Short-term Debt Issuance
-385.93MINRFY2026 · Mar 31, 2026Other Financing Charges
170.00KINRFY2026 · Mar 31, 2026Net Financing Cash Flow
-313.05MINRFY2026 · Mar 31, 2026Shares Outstanding
561.71MSharesUpdated Jul 19, 2026Float Shares
71.88MSharesUpdated Jul 19, 2026% Held by Insiders
84.18%vs all stocks
% Held by Institutions
10.76%vs all stocks
Total Cash (MRQ)
9.38BINR98.35M · vs all stocks (USD)
Total Cash per Share (MRQ)
16.71INRUpdated Jul 19, 2026Total Debt (MRQ)
539.24MINR5.65M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0177xvs Biotechnology peers
Current Ratio (MRQ)
5.54xvs Biotechnology peers
Book Value per Share (MRQ)
54.16INRUpdated Jul 19, 2026Total Assets
34.29BINR359.39M · vs all stocks (USD)
Total Current Assets
18.03BINRFY2026 · Mar 31, 2026Total Liabilities
3.87BINRFY2026 · Mar 31, 2026Total Non-current Assets
16.26BINRFY2026 · Mar 31, 2026Total Non-current Liabilities
610.60MINRFY2026 · Mar 31, 2026Total Current Liabilities
3.26BINRFY2026 · Mar 31, 2026Cash
169.85MINRFY2026 · Mar 31, 2026Cash Equivalents
2.56BINRFY2026 · Mar 31, 2026Cash & Cash Equivalents
2.73BINRFY2026 · Mar 31, 2026Other Short-term Investments
6.66BINRFY2026 · Mar 31, 2026Accounts Receivable
5.91BINRFY2026 · Mar 31, 2026Inventory
1.25BINRFY2026 · Mar 31, 2026Accounts Payable
791.59MINRFY2026 · Mar 31, 2026Short-term Debt
253.07MINRFY2026 · Mar 31, 2026Other Current Liabilities
1.63BINRFY2026 · Mar 31, 2026Long-term Debt
286.17MINRFY2026 · Mar 31, 2026Other Non-current Liabilities
-10.00KINRFY2026 · Mar 31, 2026Common Stock (Book)
1.12BINRFY2026 · Mar 31, 2026Retained Earnings
24.55BINRFY2026 · Mar 31, 2026Total Shareholders' Equity
30.43BINR318.86M · vs all stocks (USD)
52-Week Low
579.15INRUpdated Jul 19, 202652-Week High
873.50INRUpdated Jul 19, 202652-Week Change
6.39%vs all stocks
50-Day MA
770.62INRUpdated Jul 19, 2026200-Day MA
701.26INRUpdated Jul 19, 2026Avg 10-Day Volume
757.60KSharesUpdated Jul 19, 2026Avg 30-Day Volume
604.25KSharesUpdated Jul 19, 2026Diluted EPS (TTM)
10.41INRUpdated Jul 19, 20267 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Three Asset-Base Ratios Elevated
It gets more sales from its assets than its industry does, and a lot of profit from them too.
Reads
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
Operating Income Growing With Multi-Year Revenue Growth
Revenue up in each of five years, with operating income up in each of four.
Reads
ROE, ROA, And Operating ROA Elevated
It earns more on its equity than its industry does, and on its assets too — not on borrowing alone.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is 38.4%, higher than 95% of its Biotechnology peers (median -23.8%)Significant
Operating margin: 0.38Industry median: -0.24Industry P95: 0.38Peers compared: 197
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $4.57B, above the global median of $1.15BNotable
Market cap (USD): 4,574,013,420.139Global Median: 1,146,734,693.424
Levered free cash flow is $58.15M, above the global median of $16.24MNotable
Levered free cash flow (USD): 58,149,368.914Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Shanghai RAAS Blood Products Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Relay Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Humanwell Healthcare Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Beijing Tong Ren Tang Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
GenScript Biotech Corporation
Tier 1ProductionApproval-Gated PipelineSenseMakingInterface
Tianjin Pharmaceutical Da Ren Tang Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Ipca Laboratories Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
HLB Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
J.B. Chemicals & Pharmaceuticals Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Duality Biotherapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Companies that share active interpretations — structural patterns currently present in both stocks.
Pharma Research Products Co., Ltd
6 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedOperating Income Growing With Multi-Year Revenue GrowthIndustry-Benchmarked Return on Capital ElevatedThree Asset-Base Ratios Elevated
Sk Biopharmaceuticals Co., Ltd.
7 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedOperating Income Growing With Multi-Year Revenue GrowthIndustry-Benchmarked Return on Capital ElevatedThree Asset-Base Ratios Elevated
Keeper Technical Laboratory
7 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedOperating Income Growing With Multi-Year Revenue GrowthIndustry-Benchmarked Return on Capital ElevatedThree Asset-Base Ratios Elevated